66 results on '"Lewis, Basil S."'
Search Results
2. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study
- Author
-
Jankowska, Ewa A; https://orcid.org/0000-0002-9202-432X, Kirwan, Bridget-Anne, Kosiborod, Mikhail; https://orcid.org/0000-0002-3750-9789, Butler, Javed, Anker, Stefan D, McDonagh, Theresa, Dorobantu, Maria; https://orcid.org/0000-0003-1940-5262, Drozdz, Jarosław; https://orcid.org/0000-0002-0732-2104, Filippatos, Gerasimos; https://orcid.org/0000-0002-5640-0332, Keren, Andre; https://orcid.org/0000-0001-6575-4901, Khintibidze, Irakli, Kragten, Hans, Martinez, Felipe A, Metra, Marco, Milicic, Davor, Nicolau, José C; https://orcid.org/0000-0002-9680-3689, Ohlsson, Marcus; https://orcid.org/0000-0003-0043-1727, Parkhomenko, Alexander, Pascual-Figal, Domingo A; https://orcid.org/0000-0002-4993-9540, Ruschitzka, Frank; https://orcid.org/0000-0001-5972-0596, Sim, David, Skouri, Hadi; https://orcid.org/0000-0003-0541-4926, van der Meer, Peter, Lewis, Basil S; https://orcid.org/0000-0001-5604-6399, Comin-Colet, Josep; https://orcid.org/0000-0001-8780-720X, von Haehling, Stephan, Cohen-Solal, Alain, Danchin, Nicolas; https://orcid.org/0000-0001-9263-5051, Doehner, Wolfram; https://orcid.org/0000-0001-7598-708X, Dargie, Henry J, et al, Jankowska, Ewa A; https://orcid.org/0000-0002-9202-432X, Kirwan, Bridget-Anne, Kosiborod, Mikhail; https://orcid.org/0000-0002-3750-9789, Butler, Javed, Anker, Stefan D, McDonagh, Theresa, Dorobantu, Maria; https://orcid.org/0000-0003-1940-5262, Drozdz, Jarosław; https://orcid.org/0000-0002-0732-2104, Filippatos, Gerasimos; https://orcid.org/0000-0002-5640-0332, Keren, Andre; https://orcid.org/0000-0001-6575-4901, Khintibidze, Irakli, Kragten, Hans, Martinez, Felipe A, Metra, Marco, Milicic, Davor, Nicolau, José C; https://orcid.org/0000-0002-9680-3689, Ohlsson, Marcus; https://orcid.org/0000-0003-0043-1727, Parkhomenko, Alexander, Pascual-Figal, Domingo A; https://orcid.org/0000-0002-4993-9540, Ruschitzka, Frank; https://orcid.org/0000-0001-5972-0596, Sim, David, Skouri, Hadi; https://orcid.org/0000-0003-0541-4926, van der Meer, Peter, Lewis, Basil S; https://orcid.org/0000-0001-5604-6399, Comin-Colet, Josep; https://orcid.org/0000-0001-8780-720X, von Haehling, Stephan, Cohen-Solal, Alain, Danchin, Nicolas; https://orcid.org/0000-0001-9263-5051, Doehner, Wolfram; https://orcid.org/0000-0001-7598-708X, Dargie, Henry J, and et al
- Abstract
AIMS Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for the AFFIRM-AHF population. METHODS AND RESULTS The baseline 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which was completed for 1058 (535 and 523) patients in the FCM and placebo groups, respectively, was administered prior to randomization and at Weeks 2, 4, 6, 12, 24, 36, and 52. The baseline KCCQ-12 overall summary score (OSS) mean ± standard error was 38.7 ± 0.9 (FCM group) and 37.1 ± 0.8 (placebo group); corresponding values for the clinical summary score (CSS) were 40.9 ± 0.9 and 40.1 ± 0.9. At Week 2, changes in OSS and CSS were similar for FCM and placebo. From Week 4 to Week 24, patients assigned to FCM had significantly greater improvements in OSS and CSS scores vs. placebo [adjusted mean difference (95% confidence interval, CI) at Week 4: 2.9 (0.5-5.3, P = 0.018) for OSS and 2.8 (0.3-5.3, P = 0.029) for CSS; adjusted mean difference (95% CI) at Week 24: 3.0 (0.3-5.6, P = 0.028) for OSS and 2.9 (0.2-5.6, P = 0.035) for CSS]. At Week 52, the treatment effect had attenuated but remained in favour of FCM. CONCLUSION In iron-deficient patients with HF and left ventricular ejection fraction ≤50% who had stabilized after an episode of acute HF, treatment with IV FCM, compared with placebo, results in clinically meaningful beneficial effects on HRQoL as early as 4 weeks after treatment initiation, lasting up to Week 24.
- Published
- 2021
3. The age of RCT's 3 Important Aspects of RCT's in Cardiovascular Pharmacotherapy with examples from Lipid and Diabetes Trials
- Author
-
Drexel, Heinz, Rosano, Giuseppe M C, Lewis, Basil S, Huber, Kurt, Vonbank, Alexander, Dopheide, Jörn F., Mader, Arthur, Niessner, Alexander, Savarese, Gianluigi, Wassmann, Sven, and Agewall, Stefan
- Subjects
610 Medicine & health - Published
- 2020
4. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- Author
-
Mach, François, Baigent, Colin, Catapano, Alberico L, Koskinas, Konstantinos C, Casula, Manuela, Badimon, Lina, Chapman, M John, De Backer, Guy G, Delgado, Victoria, Ference, Brian A, Graham, Ian M, Halliday, Alison, Landmesser, Ulf, Mihaylova, Borislava, Pedersen, Terje R, Riccardi, Gabriele, Richter, Dimitrios J, Sabatine, Marc S, Taskinen, Marja-Riitta, Tokgozoglu, Lale, Wiklund, Olov, Mueller, Christian, Drexel, Heinz, Aboyans, Victor, Corsini, Alberto, Doehner, Wolfram, Farnier, Michel, Gigante, Bruna, Kayikcioglu, Meral, Krstacic, Goran, Lambrinou, Ekaterini, Lewis, Basil S, Masip, Josep, Moulin, Philippe, Petersen, Steffen, Petronio, Anna Sonia, Piepoli, Massimo Francesco, Pintó, Xavier, Räber, Lorenz, Ray, Kausik K, Reiner, Željko, Riesen, Walter F, Roffi, Marco, Schmid, Jean- Paul, Shlyakhto, Evgeny, Simpson, Iain A, Stroes, Erik, Sudano, Isabella, Tselepis, Alexandros D, Viigimaa, Margus, Vindis, Cecile, Vonbank, Alexander, Vrablik, Michal, Vrsalovic, Mislav, Zamorano, José Luis, Collet, Jean- Philippe, John Chapman, M, Windecker, Stephan, Collet, Jean-Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Chris P, Grobbee, Diederick, Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A, Leclercq, Christophe, Lettino, Maddalena, Merkely, Bela, Sousa-Uva, Miguel, Touyz, Rhian M, Nibouche, Djamaleddine, Zelveian, Parounak H, Siostrzonek, Peter, Najafov, Ruslan, van de Borne, Philippe, Pojskic, Belma, Postadzhiyan, Arman, Kypris, Lambros, Špinar, Jindřich, Larsen, Mogens Lytken, Eldin, Hesham Salah, Strandberg, Timo E, Ferrières, Jean, Agladze, Rusudan, Laufs, Ulrich, Rallidis, Loukianos, Bajnok, László, Gudjónsson, Thorbjörn, Maher, Vincent, Henkin, Yaakov, Gulizia, Michele Massimo, Mussagaliyeva, Aisulu, Bajraktari, Gani, Kerimkulova, Alina, Latkovskis, Gustavs, Hamoui, Omar, Slapikas, Rimvydas, Visser, Laurent, Dingli, Philip, Ivanov, Victoria, Boskovic, Aneta, Nazzi, Mbarek, Visseren, Frank, Mitevska, Irena, Retterstøl, Kjetil, Jankowski, Piotr, Fontes-Carvalho, Ricardo, Gaita, Dan, Ezhov, Marat, Foscoli, Marina, Giga, Vojislav, Pella, Daniel, Fras, Zlatko, de Isla, Leopoldo Perez, Hagström, Emil, Lehmann, Roger, Abid, Leila, Ozdogan, Oner, Mitchenko, Olena, Patel, Riyaz S, ESC Scientific Document Group, Service d’Endocrinologie, Métabolisme et Prévention des Risques Cardio-Vasculaires [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), University of Zurich, and Mach, François
- Subjects
medicine.medical_specialty ,Treatment adherence ,Evinacumab ,[SDV]Life Sciences [q-bio] ,Very low-density lipoproteins ,610 Medicine & health ,Lipoprotein remnants ,030204 cardiovascular system & hematology ,Guidelines ,Total cardiovascular risk ,2705 Cardiology and Cardiovascular Medicine ,Treatment (lifestyle) ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,medicine ,Humans ,030212 general & internal medicine ,High-density lipoproteins ,Intensive care medicine ,ComputingMilieux_MISCELLANEOUS ,Dyslipidaemias ,Triglycerides ,Dyslipidemias ,Task force ,business.industry ,Treatment (drugs) ,Lipids ,Coronary heart disease ,3. Good health ,Treatment (adherence) ,Cholesterol ,Cardiovascular Diseases ,Heart Disease Risk Factors ,10209 Clinic for Cardiology ,European atherosclerosis society ,LDL Cholesterol Lipoproteins ,Low-density lipoproteins ,Lipid modification ,Cardiology and Cardiovascular Medicine ,business ,Familial hypercholesterolaemia ,Apolipoprotein B ,All cause mortality ,Guidelines • dyslipidaemias • cholesterol • triglycerides • low-density lipoproteins • high-density lipoproteins • apolipoprotein B • lipoprotein(a) • lipoprotein remnants • total cardiovascular risk • treatment (lifestyle) • treatment (drugs) • treatment (adherence) • very low-density lipoproteins • familial hypercholesterolaemia ,Lipoprotein(a) - Abstract
The previous ESC/EAS lipid Guidelines were published in August 2016. The emergence of a substantial body of evidence over the last few years has required new, up-to-date Guidelines. New evidence has confirmed that the key initiating event in atherogenesis is the retention of low- density lipoprotein (LDL) cholesterol (LDL-C) and other cholesterol-rich apolipoprotein (Apo) B containing lipoproteins within the arterial wall. Several recent placebo-controlled clinical studies have shown that the addition of either ezetimibe or anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) to statin therapy provides a further reduction in atherosclerotic cardiovascular disease (ASCVD) risk, which is directly and positively correlated with the incrementally achieved absolute LDL-C reduction. Furthermore, these clinical trials have clearly indicated that the lower the achieved LDL-C values, the lower the risk of future cardiovascular (CV) events, with no lower limit for LDL-C values, or ‘J’-curve effect.
- Published
- 2020
- Full Text
- View/download PDF
5. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) : the Task Force for the diagnosis and management of atrialfibrillation of the European Society of Cardiology (ESC) : developed with the special contribution of the European HeartRhythm Association (EHRA) of the ESC
- Author
-
Hindricks, Gerhard, Potpara, Tatjana, Dagres, Nikolaos, Arbelo, Elena, Bax, Jeroen J., Blomström-Lundqvist, Carina, Boriani, Giuseppe, Castella, Manuel, Dan, Gheorghe-Andrei, Dilaveris, Polychronis E., Fauchier, Laurent, Petersen, Steffen E., Piccini, Jonathan P., Popescu, Bogdan A., Pürerfellner, Helmut, Richter, Dimitrios J., Roffi, Marco, Rubboli, Andrea, Scherr, Daniel, Schnabel, Renate B., Simpson, Iain A., Raatikainen, Pekka, Shlyakhto, Evgeny, Sinner, Moritz F., Steffel, Jan, Suwalski, Piotr, Svetlosak, Martin, Touyz, Rhian M., Windecker, Stephan, Baigent, Colin, Collet, Jean-Philippe, Dean, Veronica, Boveda, Serge, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Halvorsen, Sigrun, Lung, Bernard, Jüni, Peter, Petronio, Anna Sonia, Sousa Uva, Miguel, Delassi, Tahar, Sisakian, Hamayak S., Papiashvili, Giorgi, Chasnoits, Alexandr, De Pauw, Michel, Smajić, Elnur, Shalganov, Tchavdar, Avraamides, Panayiotis, Kautzner, Josef, Gerdes, Christian, Alaziz, Ahmad Abd, Kampus, Priit, Vassilikos, Vassilios P., Csanádi, Zoltán, Arnar, David O., Galvin, Joseph, Barsheshet, Alon, Caldarola, Pasquale, Rakisheva, Amina, Filippatos, Gerasimos, Bytyçi, Ibadete, Kerimkulova, Alina, Kalejs, Oskars, Njeim, Mario, Puodziukynas, Aras, Groben, Laurent, Sammut, Mark A., Grosu, Aurel, Boskovic, Aneta, Moustaghfir, Abdelhamid, Kalman, Jonathan M., de Groot, Natasja, Poposka, Lidija, Anfinsen, Ole-Gunnar, Mitkowski, Przemyslaw P., Cavaco, Diogo, Siliste, Calin, Mikhaylov, Evgeny N., Bertelli, Luca, Kojic, Dejan, Hatala, Robert, La Meir, Mark, Fras, Zlatko, Arribas, Fernando, Juhlin, Tord, Sticherling, Christian, Abid, Leila, Atar, Ilyas, Sychov, Oleg, Bates, Matthew G. D., Zakirov, Nodir U., Lane, Deirdre A., Lebeau, Jean-Pierre, Lettino, Maddalena, Lip, Gregory Y. H., Pinto, Fausto J., Thomas, G. Neil, Valgimigli, Marco, Van Gelder, Isabelle C., Van Putte, Bart P., Watkins, Caroline L., Kirchhof, Paulus, Kühne, Michael, Aboyans, Victor, Ahlsson, Anders, Balsam, Pawel, Bauersachs, Johann, Benussi, Stefano, Brandes, Axel, Braunschweig, Frieder, Camm, A. John, Capodanno, Davide, Casadei, Barbara, Conen, David, Crijns, Harry J. G. M., Delgado, Victoria, Dobrev, Dobromir, Drexel, Heinz, Eckardt, Lars, Folliguet, Thierry, Gorenek, Bulent, Haeusler, Karl Georg, Heidbuchel, Hein, Iung, Bernard, Katus, Hugo A., Kotecha, Dipak, Landmesser, Ulf, Leclercq, Christophe, Lewis, Basil S., Mascherbauer, Julia, Merino, Jose Luis, Merkely, Béla, Mont, Lluís, Mueller, Christian, Nagy, Klaudia V., Oldgren, Jonas, Pavlović, Nikola, Pedretti, Roberto F. E., and Repositório da Universidade de Lisboa
- Subjects
Rate control ,AF surgery ,Guidelines ,Upstream therapy ,Recommendations ,Left atrial appendage occlusion ,Atrial fibrillation ,Pulmonary vein isolation ,Left atrial ablation ,Antiarrhythmic drugs ,Cardioversion ,Stroke ,Anticoagulation ,Vitamin K antagonists ,Screening ,Non-vitamin K antagonist oral anticoagulants ,Rhythm control ,Catheter ablation ,ABC pathway - Abstract
© 2020 European Society of Cardiology. All rights reserved., Atrial fibrillation (AF) poses significant burden to patients, physicians, and healthcare systems globally. Substantial research efforts and resources are being directed towards gaining detailed information about the mechanisms underlying AF, its natural course and effective treatments (see also the ESC Textbook of Cardiovascular Medicine: CardioMed) and new evidence is continuously generated and published. The complexity of AF requires a multifaceted, holistic, and multidisciplinary approach to the management of AF patients, with their active involvement in partnership with clinicians. Streamlining the care of patients with AF in daily clinical practice is a challenging but essential requirement for effective management of AF. In recent years, substantial progress has been made in the detection of AF and its management, and new evidence is timely integrated in this third edition of the ESC guidelines on AF. The 2016 ESC AF Guidelines introduced the concept of the five domains to facilitate an integrated structured approach to AF care and promote consistent, guideline-adherent management for all patients. The Atrial Fibrillation Better Care (ABC) approach in the 2020 ESC AF Guidelines is a continuum of this approach, with the goal to further improve the structured management of AF patients, promote patient values, and finally improve patient outcomes.
- Published
- 2020
6. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS) : The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)
- Author
-
Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, Pepke-Zaba, Joanna, Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, and Pepke-Zaba, Joanna
- Published
- 2020
7. Antithrombotic Therapy and Major Adverse Limb Events in Patients With Chronic Lower Extremity Arterial Disease: Systematic Review and Meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases
- Author
-
Savarese, Gianluigi, Reiner, Martin F, Uijl, Alicia, D'Amario, Domenico, Agewall, Stefan, Atar, Dan, Baumgartner, Iris, Borghi, Claudio, De Carlo, Marco, Drexel, Heinz, Kaski, Juan Carlos, Kjeldsen, Keld P, Kucher, Nils, Lund, Lars H, Niessner, Alexander, Semb, Anne Grete, Schmidt, Thomas A, Sulzgruber, Patrick, Tamargo, Juan, Vitale, Cristiana, Wassmann, Sven, Aboyans, Victor, Lewis, Basil S, Savarese, Gianluigi, Reiner, Martin F, Uijl, Alicia, D'Amario, Domenico, Agewall, Stefan, Atar, Dan, Baumgartner, Iris, Borghi, Claudio, De Carlo, Marco, Drexel, Heinz, Kaski, Juan Carlos, Kjeldsen, Keld P, Kucher, Nils, Lund, Lars H, Niessner, Alexander, Semb, Anne Grete, Schmidt, Thomas A, Sulzgruber, Patrick, Tamargo, Juan, Vitale, Cristiana, Wassmann, Sven, Aboyans, Victor, and Lewis, Basil S
- Abstract
INTRODUCTION The role and selection of antithrombotic therapy to improve limb outcomes in chronic lower extremity artery disease (LEAD) is still debated. We conducted a meta-analysis to examine the efficacy and safety of anti-thrombotic and more intense antithrombotic therapy on limb outcomes and limb salvage in patients with chronic LEAD. METHODS Study inclusion criteria were: enrollment of patients with LEAD, randomized allocation to more vs. less intense antithrombotic therapy [more vs. less intense single antiplatelet therapy (SAPT); dual antiplatelet therapy (DAPT) vs. SAPT; dual antithrombotic therapy vs. SAPT or oral anticoagulant]; enrolment of ≥ 200 patients; reporting of at least one of following outcomes: limb amputation or revascularization. Seven randomized studies enrolling 30'447 patients were included. RESULTS Over a median follow-up of 24 months, more vs. less intense antithrombotic therapy or placebo significantly reduced the risk of limb revascularization (relative risk [RR]: 0.89; 95% confidence interval [CI]: 0.83 - 0.94) and limb amputation (RR: 0.63, 95% confidence interval [CI]: 0.46-0.86), as well as stroke (RR: 0.82, 95% CI: 0.70-0.97). There was no statistically significant effect on the risk of myocardial infarction (RR: 0.98, 95% CI: 0.87-1.11), all-cause (RR: 0.93, 95% CI: 0.86-1.01) and cardiovascular death (RR: 0.97, 95% CI: 0.86-1.08). Risk of major bleeding increased (RR: 1.23, 95% CI: 1.04-1.44). CONCLUSION In patients with LEAD, more intense antithrombotic therapy reduces risk of limb amputation and revascularization as well as stroke, with an increase in the risk of bleeding events.
- Published
- 2020
8. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)
- Author
-
HAG Trombose, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cancer, Global Health, Cardiovasculaire Epi Team 9, Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, Pepke-Zaba, Joanna, HAG Trombose, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cancer, Global Health, Cardiovasculaire Epi Team 9, Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, and Pepke-Zaba, Joanna
- Published
- 2020
9. Antithrombotic Therapy and Major Adverse Limb Events in Patients With Chronic Lower Extremity Arterial Disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases
- Author
-
Cardiovasculaire Epi Team 7B, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Savarese, Gianluigi, Reiner, Martin F, Uijl, Alicia, D Amario, Domenico, Agewall, Stefan, Atar, Dan, Baumgartner, Iris, Borghi, Claudio, De Carlo, Marco, Drexel, Heinz, Kaski, Juan Carlos, Kjeldsen, Keld P, Kucher, Nils, Lund, Lars H, Niessner, Alexander, Semb, Anne Grete, Schmidt, Thomas A, Sulzgruber, Patrick, Tamargo, Juan, Vitale, Cristiana, Wassmann, Sven, Aboyans, Victor, Lewis, Basil S, Cardiovasculaire Epi Team 7B, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Savarese, Gianluigi, Reiner, Martin F, Uijl, Alicia, D Amario, Domenico, Agewall, Stefan, Atar, Dan, Baumgartner, Iris, Borghi, Claudio, De Carlo, Marco, Drexel, Heinz, Kaski, Juan Carlos, Kjeldsen, Keld P, Kucher, Nils, Lund, Lars H, Niessner, Alexander, Semb, Anne Grete, Schmidt, Thomas A, Sulzgruber, Patrick, Tamargo, Juan, Vitale, Cristiana, Wassmann, Sven, Aboyans, Victor, and Lewis, Basil S
- Published
- 2020
10. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
- Author
-
Collet, Jean-Philippe, Thiele, Holger, Barbato, Emanuele, Barthélémy, Olivier, Bauersachs, Johann, Bhatt, Deepak, Dendale, Paul, Dorobantu, Maria, Edvardsen, Thor, Folliguet, Thierry, Gale, Chris, Gilard, Martine, Jobs, Alexander, Jüni, Peter, Lambrinou, Ekaterini, Lewis, Basil, Mehilli, Julinda, Meliga, Emanuele, Merkely, Béla, Mueller, Christian, Roffi, Marco, Rutten, Frans, Sibbing, Dirk, Siontis, George, Kastrati, Adnan, Mamas, Mamas, Aboyans, Victor, Angiolillo, Dominick, Bueno, Hector, Bugiardini, Raffaele, Byrne, Robert, Castelletti, Silvia, Chieffo, Alaide, Cornelissen, Veronique, Crea, Filippo, Delgado, Victoria, Drexel, Heinz, Gierlotka, Marek, Halvorsen, Sigrun, Haugaa, Kristina Hermann, Jankowska, Ewa, Katus, Hugo, Kinnaird, Tim, Kluin, Jolanda, Kunadian, Vijay, Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Meinila, Leena, Mylotte, Darren, Ndrepepa, Gjin, Omerovic, Elmir, Pedretti, Roberto, Petersen, Steffen, Petronio, Anna Sonia, Pontone, Gianluca, Popescu, Bogdan, Potpara, Tatjana, Ray, Kausik, Luciano, Flavio, Richter, Dimitrios, Shlyakhto, Evgeny, Simpson, Iain, Sousa-Uva, Miguel, Storey, Robert, Touyz, Rhian, Valgimigli, Marco, VRANCKX, PASCAL, Yeh, Robert, Collet, Jean-Philippe, Thiele, Holger, Barbato, Emanuele, Barthélémy, Olivier, Bauersachs, Johann, Bhatt, Deepak L, Dendale, Paul, Dorobantu, Maria, Edvardsen, Thor, Folliguet, Thierry, Gale, Chris P, Gilard, Martine, Jobs, Alexander, Jüni, Peter, Lambrinou, Ekaterini, Lewis, Basil S, Mehilli, Julinda, Meliga, Emanuele, Merkely, Béla, Mueller, Christian, Roffi, Marco, Rutten, Frans H, Sibbing, Dirk, Siontis, George C M, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Collet J.-P., Thiele H., Barbato E., Bauersachs J., Dendale P., Edvardsen T., Gale C.P., Jobs A., Lambrinou E., Mehilli J., Merkely B., Roffi M., Sibbing D., Kastrati A., Mamas M.A., Aboyans V., Angiolillo D.J., Bueno H., Bugiardini R., Byrne R.A., Castelletti S., Chieffo A., Cornelissen V., Crea F., Delgado V., Drexel H., Gierlotka M., Halvorsen S., Haugaa K.H., Jankowska E.A., Katus H.A., Kinnaird T., Kluin J., Kunadian V., Landmesser U., Leclercq C., Lettino M., Meinila L., Mylotte D., Ndrepepa G., Omerovic E., Pedretti R.F.E., Petersen S.E., Petronio A.S., Pontone G., Popescu B.A., Potpara T., Ray K.K., Luciano F., Richter D.J., Shlyakhto E., Simpson I.A., Sousa-Uva M., Storey R.F., Touyz R.M., Valgimigli M., Vranckx P., Yeh R.W., Barthelemy O., Bhatt D.L., Dorobantu M., Folliguet T., Gilard M., Juni P., Lewis B.S., Meliga E., Mueller C., Rutten F.H., and Siontis G.C.M.
- Subjects
unstable angina ,Myocardial ischaemia ,[SDV]Life Sciences [q-bio] ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,dual antithrombotic therapy ,Guideline ,heparin ,030204 cardiovascular system & hematology ,Platelet inhibition ,antiplatelet ,0302 clinical medicine ,ST segment ,Medicine ,dabigatran ,Myocardial infarction ,guidelines ,glycoprotein iib/iiia inhibitors ,anticoagulation ,Non-ST Elevated Myocardial Infarction ,rivaroxaban ,ComputingMilieux_MISCELLANEOUS ,reproductive and urinary physiology ,diabetes ,bleedings ,bivalirudin ,atherothrombosi ,Disease Management ,angioplasty ,Guidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable angina ,enoxaparin ,General Medicine ,Clopidogrel ,3. Good health ,early invasive strategy ,myocardial infarction ,triple therapy ,030220 oncology & carcinogenesis ,High sensitivity troponin ,embryonic structures ,Cardiology ,Platelet aggregation inhibitor ,revascularization ,biological phenomena, cell phenomena, and immunity ,Cardiology and Cardiovascular Medicine ,Ticagrelor ,medicine.drug ,Human ,recommendation ,Acute coronary syndrome ,medicine.medical_specialty ,aspirin ,glycoprotein IIb/IIIa inhibitor ,non-ST-elevation myocardial infarction ,apixaban ,rhythm monitoring ,European Society of Cardiology ,ticagrelor ,03 medical and health sciences ,nitrate ,atherothrombosis ,betablockers ,Internal medicine ,acute cardiac care ,minoca ,chest pain unit ,Diseases of the circulatory (Cardiovascular) system ,Humans ,In patient ,Acute Coronary Syndrome ,clopidogrel ,Unstable angina ,urogenital system ,nitrates ,business.industry ,fondaparinux ,betablocker ,Arrhythmias, Cardiac ,030229 sport sciences ,bleeding ,medicine.disease ,myocardial ischaemia ,platelet inhibition ,prasugrel ,diabete ,Glycoprotein IIb/IIIa inhibitors ,RC666-701 ,bypass surgery ,Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,recommendations ,edoxaban ,high-sensitivity troponin ,stent ,business ,Platelet Aggregation Inhibitors ,cangrelor - Abstract
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
- Published
- 2021
- Full Text
- View/download PDF
11. Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial.
- Author
-
Gibson CM, Duffy D, Bahit MC, Chi G, White H, Korjian S, Alexander JH, Lincoff AM, Heise M, Kingwell BA, Nicolau JC, Lopes RD, Cornel JH, Lewis BS, Vinereanu D, Goodman SG, Bode C, Steg PG, Libby P, Sacks FM, Bainey KR, Ridker PM, Mahaffey KW, Aylward P, Nicholls SJ, Pocock SJ, Mehran R, and Harrington RA
- Abstract
Background and Aims: In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary endpoint through 90 days versus placebo after acute myocardial infarction (MI). Nevertheless, given the well-established relationship between higher low-density lipoprotein cholesterol (LDL-C) and plaque burden, as well as greater risk reductions seen with PCSK9 inhibitors in patients with baseline LDL-C ≥100 mg/dL on statin therapy, the efficacy of CSL112 may be influenced by baseline LDL-C., Methods: Overall, 18,219 patients with acute MI, multivessel coronary artery disease, and additional risk factors were randomized to either four weekly infusions of 6 g CSL112 or placebo. This exploratory post-hoc analysis evaluated cardiovascular outcomes by baseline LDL-C in patients prescribed guideline-directed statin therapy at the time of randomization (n=15,731)., Results: As baseline LDL-C increased, risk of the primary endpoint at 90 days lowered in those treated with CSL112 compared with placebo. In patients with LDL-C ≥100 mg/dL at randomization, there was a significant risk reduction of cardiovascular death, MI, or stroke in the CSL112 vs. placebo group at 90, 180, and 365 days (hazard ratio 0.69 [0.53-0.90], 0.71 [0.57-0.88], and 0.78 [0.65-0.93]). In contrast, there was no difference between treatment groups among those with LDL-C <100 mg/dL at baseline., Conclusions: In this population, treatment with CSL112 compared to placebo was associated with a significantly lower risk of recurrent cardiovascular events among patients with a baseline LDL-C ≥100 mg/dL. Further studies need to confirm that CSL112 efficacy is influenced by baseline LDL-C., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
12. Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis.
- Author
-
Haller PM, Kazem N, Agewall S, Borghi C, Ceconi C, Dobrev D, Cerbai E, Grove EL, Kaski JC, Lewis BS, Niessner A, Rocca B, Rosano G, Savarese G, Schnabel RB, Semb AG, Sossalla S, Wassmann S, and Sulzgruber P
- Subjects
- Humans, Administration, Oral, Treatment Outcome, Risk Factors, Anticoagulants adverse effects, Anticoagulants administration & dosage, Heart Ventricles drug effects, Female, Risk Assessment, Male, Stroke mortality, Stroke diagnosis, Stroke prevention & control, Aged, Factor Xa Inhibitors adverse effects, Factor Xa Inhibitors administration & dosage, Vitamin K antagonists & inhibitors, Middle Aged, Thrombosis mortality, Thrombosis drug therapy, Thrombosis prevention & control, Thrombosis diagnosis, Hemorrhage chemically induced, Heart Diseases mortality, Heart Diseases diagnosis, Heart Diseases drug therapy, Heart Diseases complications
- Abstract
Aims: Direct oral anticoagulants (DOACs) are increasingly used off-label to treat patients with left ventricular thrombus (LVT). We analysed available meta-data comparing DOACs and vitamin K antagonists (VKAs) for efficacy and safety., Methods: We conducted a systematic search and meta-analysis of observational and randomized data comparing DOACs vs. VKAs in patients with LVT. Endpoints of interest were stroke or systemic embolism, thrombus resolution, all-cause death, and a composite bleeding endpoint. Estimates were pooled using a random-effects model meta-analysis, and their robustness was investigated using sensitivity and influential analyses., Results: We identified 22 articles (18 observational studies, 4 small randomized clinical trials) reporting on a total of 3587 patients (2489 VKA vs. 1098 DOAC therapy). The pooled estimates for stroke or systemic embolism [odds ratio (OR): 0.81; 95% confidence interval (CI): 0.57, 1.15] and thrombus resolution (OR: 1.12; 95% CI: 0.86, 1.46) were comparable, and there was low heterogeneity overall across the included studies. The use of DOACs was associated with lower odds of all-cause death (OR: 0.65; 95% CI: 0.46, 0.92) and a composite bleeding endpoint (OR: 0.67; 95% CI: 0.47, 0.97). A risk of bias was evident particularly for observational reports, with some publication bias suggested in funnel plots., Conclusion: In this comprehensive analysis of mainly observational data, the use of DOACs was not associated with a significant difference in stroke or systemic embolism, or thrombus resolution, compared with VKA therapy. The use of DOACs was associated with a lower rate of all-cause death and fewer bleeding events. Adequately sized randomized clinical trials are needed to confirm these findings, which could allow a wider adoption of DOACs in patients with LVT., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
13. First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA.
- Author
-
Lewis BS
- Subjects
- Humans, Gene Editing, Proprotein Convertase 9 genetics, Cardiovascular System
- Published
- 2024
- Full Text
- View/download PDF
14. SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from American Heart Association Scientific Meeting.
- Author
-
Kato ET, Ono K, and Lewis BS
- Subjects
- United States epidemiology, Humans, American Heart Association, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Myocardial Infarction diagnosis, Myocardial Infarction drug therapy
- Published
- 2024
- Full Text
- View/download PDF
15. Factor XIa inhibitors: collecting the clinical evidence.
- Author
-
Lewis BS and Hasegawa K
- Subjects
- Humans, Factor XIa, Protease Inhibitors
- Published
- 2024
- Full Text
- View/download PDF
16. GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity.
- Author
-
Kato ET, Lewis BS, and Ono K
- Subjects
- Humans, Stroke Volume, Obesity complications, Obesity diagnosis, Obesity drug therapy, Glucagon-Like Peptide-1 Receptor Agonists, Heart Failure diagnosis, Heart Failure drug therapy
- Published
- 2023
- Full Text
- View/download PDF
17. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
- Author
-
Drexel H, Tamargo J, Kaski JC, Lewis BS, Saely CH, Fraunberger P, Dobrev D, Komiyama M, Plattner T, Agewall S, and Hasegawa K
- Subjects
- Humans, Triglycerides, Cholesterol, LDL, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypertriglyceridemia diagnosis, Hypertriglyceridemia drug therapy, Hypertriglyceridemia epidemiology, Atherosclerosis drug therapy
- Abstract
Despite the atherosclerotic cardiovascular disease (ASCVD) risk reduction achieved by low-density lipoprotein cholesterol (LDL-C) lowering therapy, residual ASCVD risk still exists. Previous epidemiological studies have suggested high plasma triglyceride (TG) levels as a risk factor or risk marker for ASCVD independent of LDL-C levels. In this review, we highlighted the underlying pathophysiology of hypertriglyceridaemia, the mechanistic action of therapeutic agents, the interpretation of conflicting results on recent clinical trials, and the present options for primary and secondary prevention. The benefits of fibrates-induced reduction in TG and increase in high-density lipoprotein cholesterol might outweigh the disadvantages of increasing LDL-C levels in primary prevention. In secondary CVD prevention, using eicosapentaenoic acid without docosahexaenoic acid, in addition to statins, will be beneficial. This comprehensive review may prove useful for the development of novel approaches that target hypertriglyceridaemia in future., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
18. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
- Author
-
Eikelboom JW, Bosch J, Connolly SJ, Tyrwitt J, Fox KAA, Muehlhofer E, Neumann C, Tasto C, Bangdiwala SI, Diaz R, Alings M, Dagenais GR, Leong DP, Lonn EM, Avezum A, Piegas LS, Widimsky P, Parkhomenko AN, Bhatt DL, Branch KRH, Probstfield JL, Lopez-Jaramillo P, Rydén L, Pogosova N, Keltai K, Keltai M, Ertl G, Stoerk S, Dans AL, Lanas F, Liang Y, Zhu J, Torp-Pedersen C, Maggioni AP, Commerford PJ, Guzik TJ, Vanassche T, Verhamme P, O'Donnell M, Tonkin AM, Varigos JD, Vinereanu D, Felix C, Kim JH, Ibrahim KS, Lewis BS, Metsarinne KP, Aboyans V, Steg PG, Hori M, Kakkar A, Anand SS, Lamy A, Sharma M, and Yusuf S
- Subjects
- Humans, Infant, Aspirin, Drug Therapy, Combination, Rivaroxaban, Myocardial Infarction epidemiology, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease drug therapy, Peripheral Arterial Disease epidemiology, Stroke epidemiology
- Abstract
Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long-term open-label extension (LTOLE)., Methods and Results: Of the 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.2 years) from 455 sites in 32 countries were enrolled in LTOLE and treated with the combination of rivaroxaban and aspirin for a median of 374 additional days (range 1-1191 days). During LTOLE, the incident events per 100 patient years were as follows: for the primary outcome [cardiovascular death, stroke, or myocardial infarction (MI)] 2.35 [95% confidence interval (CI) 2.11-2.61], mortality 1.87 (1.65-2.10), stroke 0.62 (0.50-0.76), and MI 1.02 (0.86-1.19), with CIs that overlapped those seen during the randomized treatment phase with the combination of rivaroxaban and aspirin. The incidence rates for major and minor bleeding were 1.01 (0.86-1.19) and 2.49 (2.24-2.75), compared with 1.67 (1.48-1.87) and 5.11 (95% CI 4.77-5.47), respectively, during the randomized treatment phase with the combination., Conclusion: In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
19. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events.
- Author
-
Tamargo J, Kaski JC, Kimura T, Barton JC, Yamamoto K, Komiyama M, Drexel H, Lewis BS, Agewall S, and Hasegawa K
- Subjects
- Clopidogrel, Fibrinolytic Agents adverse effects, Humans, Imidazoles, Lipids, Organosilicon Compounds, Warfarin, Cardiovascular Agents, Cardiovascular Diseases, Coronary Artery Disease drug therapy, Coronary Artery Disease genetics, Hemostatics, Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Abstract
Awareness of racial/ethnic disparities represents a key challenge for healthcare systems that attempt to provide effective healthcare and to reduce existing inequalities in the use of and adherence to guideline-recommended cardiovascular drugs to improve clinical outcomes for cardiovascular disease (CVD). In this review, we describe important racial/ethnic differences between and within ethnic groups in the prevalence, risk factors, haemostatic factors, anti-inflammatory and endothelial markers, recurrence, and outcomes of CVD. We discuss important differences in the selection, doses, and response [efficacy and adverse drug reactions (ADRs)] in ethnically diverse patients treated with antithrombotics or lipid-lowering drugs. Differences in drug response are mainly related to racial/ethnic differences in the frequency of polymorphisms in genes encoding drug-metabolizing enzymes (DMEs) and drug transporters. These polymorphisms markedly influence the pharmacokinetics, dose requirements, and safety of warfarin, clopidogrel, and statins. This review aims to support a better understanding of the genetic differences between and among populations to identify patients who may experience an ADR or a lack of drug response, thus optimizing therapy and improving outcomes. The greater the understanding of the differences in the genetic variants of DMEs and transporters that determine the differences in the exposure, efficacy, and safety of cardiovascular drugs between races/ethnicities, the greater the probability that personalized medicine will become a reality., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
20. Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy.
- Author
-
Drexel H, Pocock SJ, Lewis BS, Saely CH, Kaski JC, Rosano GMC, Tautermann G, Huber K, Dopheide JF, Mader A, Niessner A, Savarese G, Schmidt TA, Semb AG, Tamargo J, Wassmann S, Clodi M, Kjeldsen KP, and Agewall S
- Subjects
- Humans, Randomized Controlled Trials as Topic, Cardiovascular System
- Published
- 2022
- Full Text
- View/download PDF
21. Are SGLT2 inhibitors effective against 'all' heart failure with preserved ejection fraction?
- Author
-
Hasegawa K and Lewis BS
- Subjects
- Humans, Stroke Volume, Ventricular Function, Left, Heart Failure diagnosis, Heart Failure drug therapy, Sodium-Glucose Transporter 2 Inhibitors adverse effects
- Published
- 2022
- Full Text
- View/download PDF
22. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial.
- Author
-
De Caterina R, Patti G, Westerbergh J, Horowitz J, Ezekowitz JA, Lewis BS, Lopes RD, McMurray JJV, Atar D, Bahit MC, Keltai M, López-Sendón JL, Ruzyllo W, Granger CB, Alexander JH, and Wallentin L
- Subjects
- Anticoagulants adverse effects, Humans, Hypoglycemic Agents adverse effects, Risk Factors, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Diabetes Mellitus diagnosis, Diabetes Mellitus drug therapy, Diabetes Mellitus epidemiology, Embolism epidemiology, Insulins therapeutic use, Myocardial Infarction diagnosis, Myocardial Infarction epidemiology, Stroke diagnosis, Stroke epidemiology, Stroke prevention & control
- Abstract
Aims: Whether diabetes without insulin therapy is an independent cardiovascular (CV) risk factor in atrial fibrillation (AF) has recently been questioned. We investigated the prognostic relevance of diabetes with or without insulin treatment in patients in the ARISTOTLE trial., Methods and Results: Patients with AF and increased stroke risk randomized to apixaban vs. warfarin were classified according to diabetes status: no diabetes; diabetes on no diabetes medications; diabetes on non-insulin antidiabetic drugs only; or insulin-treated. The associations between such patient subgroups and stroke/systemic embolism (SE), myocardial infarction (MI), and CV death were examined by Cox proportional hazard regression, both unadjusted and adjusted for other prognostic variables. Patients with diabetes were younger and had a higher body mass index. Median CHA2DS2VASc score was 4.0 in patients with diabetes and 3.0 in patients without diabetes. We found no significant difference in stroke/SE incidence across patient subgroups. Compared with no diabetes, only insulin-treated diabetes was significantly associated with higher risk. When adjusted for clinical variables, compared with no diabetes, the hazard ratios (HRs) for MI (95% confidence intervals) were for diabetes on no medication: 1.15 (0.62-2.14); for diabetes on non-insulin antidiabetic drugs: 1.32 (0.90-1.94); for insulin-treated diabetes: 2.34 (1.43-3.82); interaction P = 0.008. HRs for CV death were for diabetes on no medication: 1.19 (0.86-166); for diabetes on non-insulin antidiabetic drugs: 1.12 (0.88-1.42); for insulin-treated diabetes 1.85 (1.36-2.53), interaction P = 0.001., Conclusion: In anticoagulated patients with AF, a higher risk of MI and CV death is largely confined to diabetes treated with insulin., (© The Author(s) 2020. Published on behalf of the European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
23. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing.
- Author
-
El Hadidi S, Rosano G, Tamargo J, Agewall S, Drexel H, Kaski JC, Niessner A, Lewis BS, Coats AJS, and Savarese G
- Subjects
- Humans, Inappropriate Prescribing prevention & control, Polypharmacy, Stroke Volume, Cardiology, Heart Failure diagnosis, Heart Failure drug therapy
- Abstract
Heart failure (HF) is a chronic debilitating and potentially life-threatening condition. HF patients are usually at high risk of polypharmacy and consequently, potentially inappropriate prescribing leading to poor clinical outcomes. Based on the published literature, a comprehensive HF-specific prescribing review tool is compiled to avoid medications that may cause HF or harm HF patients and to optimize the prescribing practice of HF guideline-directed medical therapies. Recommendations are made in line with the last versions of European Society of Cardiology (ESC) guidelines, ESC position papers, scientific evidence, and experts' opinions., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
24. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
- Author
-
Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, and Caulfield MJ
- Subjects
- Europe, Humans, Pharmacogenetics, Cardiology, Cardiovascular System, Heart Failure
- Abstract
There is a strong and ever-growing body of evidence regarding the use of pharmacogenomics to inform cardiovascular pharmacology. However, there is no common position taken by international cardiovascular societies to unite diverse availability, interpretation, and application of such data, nor is there recognition of the challenges of variation in clinical practice between countries within Europe. Aside from the considerable barriers to implementing pharmacogenomic testing and the complexities of clinically actioning results, there are differences in the availability of resources and expertise internationally within Europe. Diverse legal and ethical approaches to genomic testing and clinical therapeutic application also require serious thought. As direct-to-consumer genomic testing becomes more common, it can be anticipated that data may be brought in by patients themselves, which will require critical assessment by the clinical cardiovascular prescriber. In a modern, pluralistic and multi-ethnic Europe, self-identified race/ethnicity may not be concordant with genetically detected ancestry and thus may not accurately convey polymorphism prevalence. Given the broad relevance of pharmacogenomics to areas, such as thrombosis and coagulation, interventional cardiology, heart failure, arrhythmias, clinical trials, and policy/regulatory activity within cardiovascular medicine, as well as to genomic and pharmacology subspecialists, this position statement attempts to address these issues at a wide-ranging level., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
25. Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
- Author
-
Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, and Caulfield MJ
- Subjects
- Europe, Humans, Pharmacogenetics, Cardiology, Cardiovascular System
- Abstract
Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
26. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
- Author
-
Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabés JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylén I, Tolosana JM, Leyva F, Linde C, Abdelhamid M, Aboyans V, Arbelo E, Asteggiano R, Barón-Esquivias G, Bauersachs J, Biffi M, Birgersdotter-Green U, Bongiorni MG, Borger MA, Čelutkienė J, Cikes M, Daubert JC, Drossart I, Ellenbogen K, Elliott PM, Fabritz L, Falk V, Fauchier L, Fernández-Avilés F, Foldager D, Gadler F, De Vinuesa PGG, Gorenek B, Guerra JM, Hermann Haugaa K, Hendriks J, Kahan T, Katus HA, Konradi A, Koskinas KC, Law H, Lewis BS, Linker NJ, Løchen ML, Lumens J, Mascherbauer J, Mullens W, Nagy KV, Prescott E, Raatikainen P, Rakisheva A, Reichlin T, Ricci RP, Shlyakhto E, Sitges M, Sousa-Uva M, Sutton R, Suwalski P, Svendsen JH, Touyz RM, Van Gelder IC, Vernooy K, Waltenberger J, Whinnett Z, and Witte KK
- Subjects
- Cardiac Pacing, Artificial, Humans, Stroke Volume, Atrial Fibrillation therapy, Cardiac Resynchronization Therapy adverse effects, Heart Failure diagnosis, Heart Failure therapy
- Published
- 2022
- Full Text
- View/download PDF
27. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
- Author
-
Krogager ML, Kragholm K, Thomassen JQ, Søgaard P, Lewis BS, Wassmann S, Baumgartner I, Ceconi C, Schmidt TA, Kaski JC, Drexel H, Semb AG, Agewall S, Niessner A, Savarese G, Kjeldsen KP, Borghi C, Tamargo J, and Torp-Pedersen C
- Subjects
- Goals, Humans, Potassium, Cardiology, Cardiovascular Diseases diagnosis, Cardiovascular Diseases drug therapy, Cardiovascular Diseases epidemiology, Hypokalemia diagnosis, Hypokalemia drug therapy
- Abstract
Hypokalaemia is common in patients with cardiovascular disease. In this review, we emphasize the importance of tight potassium regulation in patients with cardiovascular disease based on findings from observational studies. To enhance the understanding, we also describe the mechanisms of potassium homeostasis maintenance, the most common causes of hypokalaemia and present strategies for monitoring and management of low potassium levels. We propose elevation of potassium in asymptomatic patients with lower normal concentrations and concurrent cardiovascular disease. These proposals are intended to assist clinicians until more evidence is available., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
28. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy.
- Author
-
Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, Collet JP, Drexel H, Espinola-Klein C, Lewis BS, Roffi M, Sibbing D, Sillesen H, Stabile E, Schlager O, and De Carlo M
- Subjects
- Anticoagulants therapeutic use, Aorta, Consensus, Fibrinolytic Agents therapeutic use, Humans, Platelet Aggregation Inhibitors adverse effects, Peripheral Arterial Disease drug therapy, Thrombosis drug therapy, Thrombosis prevention & control
- Abstract
The aim of this collaborative document is to provide an update for clinicians on best antithrombotic strategies in patients with aortic and/or peripheral arterial diseases. Antithrombotic therapy is a pillar of optimal medical treatment for these patients at very high cardiovascular risk. While the number of trials on antithrombotic therapies in patients with aortic or peripheral arterial diseases is substantially smaller than for those with coronary artery disease, recent evidence deserves to be incorporated into clinical practice. In the absence of specific indications for chronic oral anticoagulation due to concomitant cardiovascular disease, a single antiplatelet agent is the basis for long-term antithrombotic treatment in patients with aortic or peripheral arterial diseases. Its association with another antiplatelet agent or low-dose anticoagulants will be discussed, based on patient's ischaemic and bleeding risk as well therapeutic paths (e.g. endovascular therapy). This consensus document aims to provide a guidance for antithrombotic therapy according to arterial disease localizations and clinical presentation. However, it cannot substitute multidisciplinary team discussions, which are particularly important in patients with uncertain ischaemic/bleeding balance. Importantly, since this balance evolves over time in an individual patient, a regular reassessment of the antithrombotic therapy is of paramount importance., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
29. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials.
- Author
-
Drexel H, Lewis BS, Rosano GMC, Saely CH, Tautermann G, Huber K, Dopheide JF, Kaski JC, Mader A, Niessner A, Savarese G, Schmidt TA, Semb A, Tamargo J, Wassmann S, Per Kjeldsen K, Agewall S, and Pocock SJ
- Subjects
- Humans, Lipids, Randomized Controlled Trials as Topic, Research Design, Diabetes Mellitus diagnosis, Diabetes Mellitus drug therapy, Fibrinolytic Agents adverse effects
- Abstract
This review article aims to explain the important issues that data safety monitoring boards (DSMB) face when considering early termination of a trial and is specifically addressed to the needs of clinical and research cardiologists. We give an insight into the overall background and then focus on the three principal reasons for stopping trials, i.e. efficacy, futility, and harm. The statistical essentials are also addressed to familiarize clinicians with the key principles. The topic is further highlighted by numerous examples from lipid trials and antithrombotic trials. This is followed by an overview of regulatory aspects, including an insight into industry-investigator interactions. To conclude, we summarize the key elements that are the basis for a decision to stop a randomized clinical trial (RCT)., (Published on behalf of the European Society of Cardiology. © The Author(s) 2020.)
- Published
- 2021
- Full Text
- View/download PDF
30. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.
- Author
-
Bosch J, Lonn EM, Jung H, Zhu J, Liu L, Lopez-Jaramillo P, Pais P, Xavier D, Diaz R, Dagenais G, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Held C, Peters RJG, Lewis BS, Jansky P, Yusoff K, Khunti K, Toff WD, Reid CM, Varigos J, Joseph P, Leiter LA, and Yusuf S
- Subjects
- Blood Pressure, Cholesterol, Double-Blind Method, Follow-Up Studies, Humans, Risk Factors, Cardiovascular Diseases prevention & control, Myocardial Infarction prevention & control
- Abstract
Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) events by 24% in 12 705 participants at intermediate CV risk after 5.6 years. There was no benefit of blood pressure (BP) lowering treatment in the overall group, but a reduction in events in the third of participants with elevated systolic BP. After cessation of all the trial medications, we examined whether the benefits observed during the active treatment phase were sustained, enhanced, or attenuated., Methods and Results: After the randomized treatment period (5.6 years), participants were invited to participate in 3.1 further years of observation (total 8.7 years). The first co-primary outcome for the entire length of follow-up was the composite of myocardial infarction, stroke, or CV death [major adverse cardiovascular event (MACE)-1], and the second was MACE-1 plus resuscitated cardiac arrest, heart failure, or coronary revascularization (MACE-2). In total, 9326 (78%) of 11 994 surviving Heart Outcomes Prevention Evaluation (HOPE)-3 subjects consented to participate in extended follow-up. During 3.1 years of post-trial observation (total follow-up of 8.7 years), participants originally randomized to rosuvastatin compared with placebo had a 20% additional reduction in MACE-1 [95% confidence interval (CI), 0.64-0.99] and a 17% additional reduction in MACE-2 (95% CI 0.68-1.01). Therefore, over the 8.7 years of follow-up, there was a 21% reduction in MACE-1 (95% CI 0.69-0.90, P = 0.005) and 21% reduction in MACE-2 (95% CI 0.69-0.89, P = 0.002). There was no benefit of BP lowering in the overall study either during the active or post-trial observation period, however, a 24% reduction in MACE-1 was observed over 8.7 years., Conclusion: The CV benefits of rosuvastatin, and BP lowering in those with elevated systolic BP, compared with placebo continue to accrue for at least 3 years after cessation of randomized treatment in individuals without cardiovascular disease indicating a legacy effect., Trial Registration Number: NCT00468923., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2021
- Full Text
- View/download PDF
31. Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy.
- Author
-
Crea F, Thiele H, Sibbing D, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Siontis GCM, Barbato E, Collet JP, Giannitsis E, Hamm CW, Böhm M, Cornel JH, Ferreiro JL, Frey N, Huber K, Kubica J, Navarese EP, Mehran R, Morais J, Storey RF, Valgimigli M, Vranckx P, and James S
- Subjects
- Clopidogrel, Humans, Prasugrel Hydrochloride therapeutic use, Purinergic P2Y Receptor Antagonists, Ticagrelor therapeutic use, Percutaneous Coronary Intervention
- Published
- 2021
- Full Text
- View/download PDF
32. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
- Author
-
Jankowska EA, Kirwan BA, Kosiborod M, Butler J, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Filippatos G, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Friede T, Fabien V, Dorigotti F, Pocock S, and Ponikowski P
- Subjects
- Humans, Ferric Compounds therapeutic use, Iron therapeutic use, Maltose therapeutic use, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Anemia, Iron-Deficiency drug therapy, Heart Failure complications, Heart Failure drug therapy, Quality of Life
- Abstract
Aims: Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for the AFFIRM-AHF population., Methods and Results: The baseline 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which was completed for 1058 (535 and 523) patients in the FCM and placebo groups, respectively, was administered prior to randomization and at Weeks 2, 4, 6, 12, 24, 36, and 52. The baseline KCCQ-12 overall summary score (OSS) mean ± standard error was 38.7 ± 0.9 (FCM group) and 37.1 ± 0.8 (placebo group); corresponding values for the clinical summary score (CSS) were 40.9 ± 0.9 and 40.1 ± 0.9. At Week 2, changes in OSS and CSS were similar for FCM and placebo. From Week 4 to Week 24, patients assigned to FCM had significantly greater improvements in OSS and CSS scores vs. placebo [adjusted mean difference (95% confidence interval, CI) at Week 4: 2.9 (0.5-5.3, P = 0.018) for OSS and 2.8 (0.3-5.3, P = 0.029) for CSS; adjusted mean difference (95% CI) at Week 24: 3.0 (0.3-5.6, P = 0.028) for OSS and 2.9 (0.2-5.6, P = 0.035) for CSS]. At Week 52, the treatment effect had attenuated but remained in favour of FCM., Conclusion: In iron-deficient patients with HF and left ventricular ejection fraction <50% who had stabilized after an episode of acute HF, treatment with IV FCM, compared with placebo, results in clinically meaningful beneficial effects on HRQoL as early as 4 weeks after treatment initiation, lasting up to Week 24., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2021
- Full Text
- View/download PDF
33. Atrial fibrillation and stroke prevention.
- Author
-
Lewis BS
- Subjects
- Humans, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Stroke diagnosis, Stroke epidemiology, Stroke prevention & control
- Published
- 2021
- Full Text
- View/download PDF
34. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
- Author
-
Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, and Siontis GCM
- Subjects
- Disease Management, Humans, Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome therapy
- Published
- 2021
- Full Text
- View/download PDF
35. MSc in clinical trials: a new flagship Working Group project.
- Author
-
Lewis BS, Agewall S, and Rosano GMC
- Subjects
- Humans, Clinical Trials as Topic, Research Design, Research Personnel education
- Published
- 2020
- Full Text
- View/download PDF
36. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.
- Author
-
Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, and Agewall S
- Subjects
- Biomarkers blood, Blood Glucose metabolism, Cardiovascular Diseases diagnosis, Cardiovascular Diseases mortality, Diabetes Mellitus blood, Diabetes Mellitus diagnosis, Diabetes Mellitus mortality, Dyslipidemias blood, Dyslipidemias diagnosis, Dyslipidemias mortality, Humans, Hypoglycemic Agents adverse effects, Hypolipidemic Agents adverse effects, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Blood Glucose drug effects, Cardiovascular Diseases prevention & control, Diabetes Mellitus drug therapy, Dyslipidemias drug therapy, Endpoint Determination, Hypoglycemic Agents therapeutic use, Hypolipidemic Agents therapeutic use, Lipids blood, Randomized Controlled Trials as Topic methods, Research Design
- Abstract
Randomized clinical trials (RCTs) are important and the Gold Standard for drugs in modern cardiovascular (CV) therapy. The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. It is important to select an appropriate endpoint. Efficacy endpoints must be clinically relevant and can be hierarchically divided. A very interesting innovation in endpoint acquisition is the total event paradigm., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
37. Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases.
- Author
-
Savarese G, Reiner MF, Uijl A, D'Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, and Lewis BS
- Subjects
- Administration, Oral, Aged, Amputation, Surgical, Anticoagulants adverse effects, Chronic Disease, Dual Anti-Platelet Therapy, Female, Fibrinolytic Agents adverse effects, Hemorrhage chemically induced, Humans, Limb Salvage, Male, Middle Aged, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease mortality, Platelet Aggregation Inhibitors adverse effects, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Stroke mortality, Stroke prevention & control, Time Factors, Treatment Outcome, Anticoagulants administration & dosage, Fibrinolytic Agents administration & dosage, Lower Extremity blood supply, Peripheral Arterial Disease drug therapy, Platelet Aggregation Inhibitors administration & dosage
- Abstract
Aims: The role and selection of antithrombotic therapy to improve limb outcomes in chronic lower extremity artery disease (LEAD) is still debated. We conducted a meta-analysis to examine the efficacy and safety of antithrombotic and more intense antithrombotic therapy on limb outcomes and limb salvage in patients with chronic LEAD., Methods and Results: Study inclusion criteria were: enrolment of patients with LEAD, randomized allocation to more vs. less intense antithrombotic therapy [more vs. less intense single-antiplatelet therapy (SAPT); dual-antiplatelet therapy vs. SAPT; dual antithrombotic therapy vs. SAPT or oral anticoagulant]; enrolment of ≥200 patients; reporting of at least one of following outcomes: limb amputation or revascularization. Seven randomized studies enrolling 30 447 patients were included. Over a median follow-up of 24 months, more vs. less intense antithrombotic therapy or placebo significantly reduced the risk of limb revascularization [relative risk (RR) 0.89, 95% confidence interval (CI) 0.83-0.94] and limb amputation (RR 0.63, 95% CI 0.46-0.86), as well as stroke (RR 0.82, 95% CI 0.70-0.97). There was no statistically significant effect on the risk of myocardial infarction (RR 0.98, 95% CI 0.87-1.11), all-cause (RR 0.93, 95% CI 0.86-1.01), and cardiovascular death (RR 0.97, 95% CI 0.86-1.08). Risk of major bleeding increased (RR 1.23, 95% CI 1.04-1.44)., Conclusion: In patients with LEAD, more intense antithrombotic therapy reduces the risk of limb amputation and revascularization as well as stroke with an increase in the risk of bleeding events., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
38. Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.
- Author
-
Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, and Niessner A
- Subjects
- Administration, Oral, Decision Trees, Hemorrhage chemically induced, Humans, Patient Preference, Practice Guidelines as Topic, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Risk Assessment, Stroke prevention & control
- Published
- 2019
- Full Text
- View/download PDF
39. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review.
- Author
-
Vonbank A, Drexel H, Agewall S, Lewis BS, Dopheide JF, Kjeldsen K, Ceconi C, Savarese G, Rosano G, Wassmann S, Niessner A, Schmidt TA, Saely CH, Baumgartner I, and Tamargo J
- Subjects
- Adult, Aged, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Drug Administration Schedule, Dyslipidemias diagnosis, Dyslipidemias epidemiology, Female, Guideline Adherence, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Male, Middle Aged, Observational Studies as Topic standards, Practice Guidelines as Topic, Randomized Controlled Trials as Topic standards, Risk Factors, Treatment Outcome, Cardiovascular Diseases prevention & control, Dyslipidemias drug therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Medication Adherence, Observational Studies as Topic methods, Practice Patterns, Physicians' standards, Randomized Controlled Trials as Topic methods, Research Design standards
- Abstract
With statins, the reported rate of adverse events differs widely between randomized clinical trials (RCTs) and observations in clinical practice, the rates being 1-2% in RCTs vs. 10-20% in the so-called real world. One possible explanation is the claim that RCTs mostly use a run-in period with a statin. This would exclude intolerant patients from remaining in the trial and therefore favour a bias towards lower rates of intolerance. We here review data from RCTs with more than 1000 participants with and without a run-in period, which were included in the Cholesterol Treatment Trialists Collaboration. Two major conclusions arise: (i) the majority of RCTs did not have a test dose of a statin in the run-in phase. (ii) A test dose in the run-in phase was not associated with a significantly improved adherence rate within that trial when compared to trials without a test dose. Taken together, the RCTs of statins reviewed here do not suggest a bias towards an artificially higher adherence rate because of a run-in period with a test dose of the statin. Other possible explanations for the apparent disparity between RCTs and real-world observations are also included in this review albeit mostly not supported by scientific data.
- Published
- 2018
- Full Text
- View/download PDF
40. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
- Author
-
Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, Ponikowski P, Savarese G, Schmidt TA, Seferovic P, Wassmann S, Walther T, and Lewis BS
- Subjects
- Biomarkers blood, Cardiovascular Diseases epidemiology, Cardiovascular Diseases physiopathology, Consensus, Humans, Hyperkalemia blood, Hyperkalemia chemically induced, Hyperkalemia epidemiology, Potassium blood, Recurrence, Renal Insufficiency, Chronic epidemiology, Renal Insufficiency, Chronic physiopathology, Risk Factors, Treatment Outcome, Angiotensin Receptor Antagonists adverse effects, Angiotensin-Converting Enzyme Inhibitors adverse effects, Cardiology standards, Cardiovascular Diseases drug therapy, Hyperkalemia therapy, Mineralocorticoid Receptor Antagonists adverse effects, Renin-Angiotensin System drug effects
- Abstract
Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard endpoints. Renin angiotensin aldosterone system inhibitors are also the basis in treatment of arterial hypertension, and they are furthermore indicated to reduce events and target organ damage in patients with diabetes and chronic kidney disease, where they have specific indication because of the evidence of benefit. Renin angiotensin aldosterone system inhibitor therapy, however, is associated with an increased risk of hyperkalaemia. Patients with chronic kidney disease and HF are at increased risk of hyperkalaemia and ∼50% of these patients experience two or more yearly recurrences. A substantial proportion of patients receiving RAASi therapy have their therapy down-titrated or more often discontinued even after a single episode of elevated potassium (K+) level. Since RAASi therapy reduces mortality and morbidity in patients with cardiovascular disease steps should, when hyperkalaemia develops, be considered to lower K+ level and enable patients to continue their RAASi therapy. The use of such measures are especially important in those patients with the most to gain from RAASi therapy.
- Published
- 2018
- Full Text
- View/download PDF
41. Peripheral arterial disease and limb salvage: a new arena for the cardiologist.
- Author
-
Lewis BS and Atar D
- Subjects
- Amputation, Surgical, Fibrinolytic Agents adverse effects, Humans, Ischemia diagnosis, Ischemia mortality, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease mortality, Risk Factors, Treatment Outcome, Cardiologists, Fibrinolytic Agents therapeutic use, Ischemia drug therapy, Limb Salvage, Peripheral Arterial Disease drug therapy
- Published
- 2018
- Full Text
- View/download PDF
42. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
- Author
-
Niessner A, Tamargo J, Koller L, Saely CH, Schmidt TA, Savarese G, Wassmann S, Rosano G, Ceconi C, Torp-Pedersen C, Kaski JC, Kjeldsen KP, Agewall S, Walther T, Drexel H, and Lewis BS
- Subjects
- Cardiology, Cardiovascular Diseases complications, Diabetes Mellitus, Type 2 complications, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Europe, Glucagon-Like Peptide-1 Receptor agonists, Glycated Hemoglobin metabolism, Glycoside Hydrolase Inhibitors therapeutic use, Humans, Incretins therapeutic use, Metformin therapeutic use, Myocardial Infarction epidemiology, Societies, Medical, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Stroke epidemiology, Cardiovascular Diseases prevention & control, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents therapeutic use
- Published
- 2018
- Full Text
- View/download PDF
43. Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE.
- Author
-
Goto S, Merrill P, Wallentin L, Wojdyla DM, Hanna M, Avezum A, Easton JD, Harjola VP, Huber K, Lewis BS, Parkhomenko A, Zhu J, Granger CB, Lopes RD, and Alexander JH
- Subjects
- Aged, Aged, 80 and over, Atrial Fibrillation complications, Cause of Death trends, Female, Follow-Up Studies, Global Health, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Survival Rate trends, Thromboembolism epidemiology, Thromboembolism etiology, Treatment Outcome, Atrial Fibrillation drug therapy, Fibrinolytic Agents therapeutic use, Risk Assessment methods, Thromboembolism prevention & control
- Abstract
Aims: We investigated baseline characteristics, antithrombotic use, and clinical outcomes of patients with atrial fibrillation (AF) and a thrombo-embolic event in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study to better inform the care of these high-risk patients., Method and Results: Thrombo-embolic events were defined as stroke (ischaemic or unknown cause) or systemic embolism (SE). Clinical outcomes were estimated using the Kaplan-Meier method. All-cause mortality and International Society on Thrombosis and Haemostasis (ISTH) major bleeding after events were analysed using a Cox proportional hazards model with time-dependent covariates. Of 18 201 patients in ARISTOTLE, 365 experienced a thrombo-embolic event [337 strokes (ischaemic or unknown cause), 28 SE]; 46 (12.6%) of which were fatal. In the 30 days before and after a thrombo-embolic event, 11% and 37% of patients, respectively, were not taking an oral anticoagulant. During follow-up (median 1.8 years), 22 patients (7.1%/year) had a recurrent stroke, 97 (30.1%/year) died, and 10 (6.7%/year) had major bleeding. Compared with patients without a thrombo-embolic event, the short- and long-term adjusted hazards of death in patients with a thrombo-embolic event were high [≤30 days: hazard ratio (HR) 54.3%, 95% confidence interval (95% CI) 41.4-71.3; >30 days: HR 3.5, 95% CI 2.5-4.8; both P < 0.001]. The adjusted hazards of major bleeding were also high short-term (HR 10.37, 95% CI 3.87-27.78; P < 0.001) but not long-term (HR 1.7, 95% CI: 0.77-3.88; P = 0.18)., Conclusions: Thrombo-embolic events were rare but associated with high short- and long-term morbidity and mortality. Substantial numbers of patients are not receiving oral anticoagulattherapy before and, despite this risk, after a first thrombo-embolic event., Clinical Trial Registration: ClinicalTrials.gov (NCT00412984).
- Published
- 2018
- Full Text
- View/download PDF
44. Comprehensive efforts to increase adherence to statin therapy.
- Author
-
Vonbank A, Agewall S, Kjeldsen KP, Lewis BS, Torp-Pedersen C, Ceconi C, Funck-Brentano C, Kaski JC, Niessner A, Tamargo J, Walther T, Wassmann S, Rosano G, Schmidt H, Saely CH, and Drexel H
- Subjects
- Cardiology organization & administration, Cardiovascular Diseases drug therapy, Cardiovascular Diseases mortality, Cardiovascular Diseases prevention & control, Humans, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Medication Adherence
- Published
- 2017
- Full Text
- View/download PDF
45. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis.
- Author
-
Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE, Torp-Pedersen C, Kjeldsen K, Lewis BS, Drexel H, Kaski JC, Atar D, Storey RF, Lip GYH, Verheugt FWA, and Agewall S
- Subjects
- Administration, Oral, Antibodies, Monoclonal, Humanized therapeutic use, Arginine administration & dosage, Arginine analogs & derivatives, Consensus, Dabigatran antagonists & inhibitors, Evidence-Based Medicine, Factor Xa administration & dosage, Forecasting, Hemorrhage chemically induced, Humans, Piperazines administration & dosage, Recombinant Proteins administration & dosage, Risk Factors, Anticoagulants administration & dosage, Antidotes therapeutic use, Thrombosis drug therapy, Vitamin K antagonists & inhibitors
- Published
- 2017
- Full Text
- View/download PDF
46. Cardiovascular pharmacotherapy-2015 was a good year.
- Author
-
Lewis BS
- Subjects
- Europe, Humans, Cardiovascular Agents therapeutic use, Cardiovascular Diseases drug therapy, Periodicals as Topic
- Published
- 2016
- Full Text
- View/download PDF
47. Resting heart rate and measures of effort-related cardiac autonomic dysfunction predict cardiovascular events in asymptomatic type 2 diabetes.
- Author
-
Zafrir B, Azencot M, Dobrecky-Mery I, Lewis BS, Flugelman MY, and Halon DA
- Subjects
- Aged, Asymptomatic Diseases, Cardiovascular Diseases complications, Cardiovascular Diseases mortality, Cause of Death trends, Diabetes Mellitus, Type 2 mortality, Diabetes Mellitus, Type 2 physiopathology, Exercise Test, Female, Follow-Up Studies, Humans, Israel epidemiology, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Survival Rate trends, Autonomic Nervous System physiopathology, Cardiovascular Diseases physiopathology, Diabetes Mellitus, Type 2 complications, Exercise Tolerance physiology, Heart Rate physiology, Rest physiology, Risk Assessment methods
- Abstract
Background: Autonomic control of the cardiovascular system may be impaired in type 2 diabetes and is associated with increased morbidity and mortality. Parameters obtained during stress testing may reflect early stages of cardiac autonomic dysfunction and provide prognostic information in asymptomatic type 2 diabetes., Methods: We performed maximal exercise treadmill testing in 594 patients with type 2 diabetes without known coronary heart disease. The prognostic significance of physiological parameters associated with autonomic dysfunction was assessed, including chronotropic incompetence (<80% heart rate reserve), abnormal heart rate recovery at 1 minute <18 beats/minute, and resting tachycardia >100 beats/minute. Cox proportional hazards analysis was used to determine the association of exercise parameters with a composite outcome of all-cause mortality, myocardial infarction or stroke., Results: Resting heart rate >100 beats/minute was observed in 18% of patients, chronotropic incompetence in 30% and heart rate recovery at 1 minute <18 beats/minute in 35%. Over 79 ± 16 months, there were 72 (12%) events. Each parameter was significantly associated with event risk in an adjusted multivariate analysis: chronotropic incompetence (hazard ratio 1.89, 95% confidence interval 1.18-3.01; P = 0.008), resting heart rate ≥100 beats/minute (hazard ratio 1.97, 95% confidence interval 1.19-3.26; P = 0.008) and heart rate recovery at 1 minute <18 beats (hazard ratio 1.77, 95% confidence interval 1.12-2.81; P = 0.015). A progressive relationship between the number of abnormal parameters and event risk was observed (log rank P < 0.001)., Conclusions: Chronotropic incompetence, resting tachycardia and reduced heart rate recovery are independently and additively associated with long-term mortality, myocardial infarction or stroke in type 2 diabetes without known coronary heart disease., (© The European Society of Cardiology 2015.)
- Published
- 2016
- Full Text
- View/download PDF
48. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
- Author
-
Schmidt M, Lamberts M, Olsen AM, Fosbøll E, Niessner A, Tamargo J, Rosano G, Agewall S, Kaski JC, Kjeldsen K, Lewis BS, and Torp-Pedersen C
- Subjects
- Atrial Fibrillation complications, Cyclooxygenase Inhibitors adverse effects, Drug Approval, Drug Therapy, Combination, Fibrinolytic Agents adverse effects, Heart Failure complications, Hemostasis drug effects, Humans, Intraoperative Complications chemically induced, Myocardial Infarction complications, Observational Studies as Topic, Public Health, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Safety-Based Drug Withdrawals, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Cardiovascular Diseases chemically induced
- Published
- 2016
- Full Text
- View/download PDF
49. CardioPulse: Coronary artery disease from prevention to intervention.
- Author
-
Lewis BS
- Subjects
- Cardiac Imaging Techniques, Congresses as Topic, Humans, Hyperlipidemias prevention & control, Italy, PCSK9 Inhibitors, Thoracic Surgical Procedures, Transcatheter Aortic Valve Replacement, Coronary Artery Disease prevention & control
- Published
- 2016
50. Annual report of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
- Author
-
Lewis BS and Agewall S
- Subjects
- Congresses as Topic, Echocardiography, Europe, Heart Failure, Humans, Periodicals as Topic, Practice Guidelines as Topic, Cardiology, Cardiovascular Diseases drug therapy, Societies, Medical
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.